Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06079255
Other study ID # IDEA
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date December 15, 2023
Est. completion date February 1, 2026

Study information

Verified date October 2023
Source Oslo University Hospital
Contact John Clarke-Jenssen, MD, PhD.
Phone 23027447
Email uxclaj@ous-hf.no
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is an open, observational, prospective, descriptive, single-centre study including 60 patients. The study is designed to investigate if IscAlert sensor system can be used for reliable and continuous tissue carbon dioxide (pCO2)- and temperature monitoring in muscular tissue in lower extremity in patients at risk of developing acute compartment syndrome.


Description:

This is an open, observational, prospective, descriptive, single-centre study including 60 patients. The study is designed to investigate if IscAlert sensor system can be used for reliable and continuous tissue carbon dioxide (pCO2)- and temperature monitoring in muscular tissue in lower extremity in patients at risk of developing acute compartment syndrome. The study will provide information regarding the clinical usefulness of tissue perfusion assessment by pCO2 and temperature monitoring in the diagnosis of patients at risk of developing acute compartment syndrome. Additionally, it will provide information regarding limits of pCO2 and temperature in the tissue indicating the need for fasciotomy. A fasciotomy will be performed independent of the measured pCO2 and temperature measurements in the muscle if clinical signs indicate a development of possible acute compartment syndrome. Measures of pain, and number of infections and bleeding caused by (or assumed to be caused by IscAlert) at insertion site will be registered. The duration of investigation: In a patient: From insertion of first IscAlertâ„¢ sensor(s) to discharge from hospital. The sensors will usually be implanted for two days each. Follow up until 30 days after discharge from the hospital. 13 months of inclusion of all patients. There will be one last follow-up visit 1 year after discharge which will only look at sequelae after acute compartment syndrome and not sensors related issues. Primary Aim: To assess if pCO2-levels when assessed with IscAlert correctly indicate the presence of acute compartment syndrome in muscular tissue in lower extremity in patients at risk of developing acute compartment syndrome. Hypotheses 1. The pCO2 measurements will be at least 3 kPa higher when assessed with IscAlert in the muscle compartment where acute compartment syndrome develops compared to compartments where acute compartment syndrome does not develop. 2. No clinically significant pain, bleeding or infection will occur due to using IscAlert. 3. The temperature measurements will be lower when assessed with IscAlert in the muscle compartment where acute compartment syndrome develops compared to compartments where acute compartment syndrome does not develop.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 60
Est. completion date February 1, 2026
Est. primary completion date February 1, 2025
Accepts healthy volunteers
Gender All
Age group 18 Years to 110 Years
Eligibility Inclusion Criteria: - Must have a leg fracture that, perceived by the clinician, could give rise to later developing acute compartment syndrome condition. - Subject must be 18 years or more. - Able to sign informed consent. - Expected cooperation of the patients for the treatment and follow up Exclusion Criteria: - Another study interfering with current study - Any reason why, in the opinion of the investigator, the patient should not participate. - Patients where a fasciotomy has already been decided should be performed

Study Design


Intervention

Device:
IscAlert sensor(s) in patient with risk of acute compartment syndrome
of the replanted extremity Insertion of a CO2- and temperature sensor(s) (IscAlert) in the anterior compartment of a lower limb (leg)

Locations

Country Name City State
Norway Oslo University Hospital Oslo

Sponsors (2)

Lead Sponsor Collaborator
Oslo University Hospital Sensocure AS

Country where clinical trial is conducted

Norway, 

Outcome

Type Measure Description Time frame Safety issue
Primary Tissue CO2-level Tissue CO2-level (kPa) during insertion period 10 days
Secondary Bleeding Amount of blood from insertion site (ml) 10 days
Secondary Infection Infection from insertion site at the discretion of the investigator (yes or no) 30 days
Secondary Pain at sensor insertion site Pain at the insertion site measured by Numeric Rating Scale (0= no pain, 10= maximum pain) 30 days
Secondary Pain in the lower leg during hospitalisation Pain in the injured lower leg measured by Numeric Rating Scale (0= no pain, 10= maximum pain) 10 days
Secondary Color of the lower leg Skin color of the injured lower leg (Blue/Pink/Pale/Normal) during hospitalisation 10 days
Secondary Paresthesia of the lower leg Paresthesia of the injured lower leg (Yes/No) during hospitalisation 10 days
Secondary Paralysis of the lower leg Paralysis of the injured lower leg (Yes/No) during hospitalisation 10 days
Secondary Lenght of sensor implantation time Lenght of sensor implantation time during hospitalisation 10 days
Secondary Time to discovery of reduced blood flow in lower leg Number of days and hours from primary surgery end to obstructed blood flow is diagnosed. 10 days
Secondary Number of re-operations Number of reoperations (fasciotomies) caused by acute compartment syndrome 30 days
Secondary Number of skin grafts performed Number of skin grafts performed caused by sequelae after acute compartment syndrome 1 year
Secondary Number of limb amputations performed Number of limb amputations performed caused by sequelae after acute compartment syndrome 1 year
Secondary Number of sensory deficit conditions Number of sensory deficit conditions caused by sequelae after acute compartment syndrome 1 year
Secondary Number of paralysis conditions Number of paralysis conditions caused by sequelae after acute compartment syndrome 1 year
Secondary Number of rhabdomyolysis conditions Number of rhabdomyolysis conditions caused by sequelae after acute compartment syndrome 1 year
Secondary Number of limb muscle contractures Number of limb muscle contractures caused by sequelae after acute compartment syndrome 1 year
Secondary Number of acute compartment syndrome conditions during hospitalisation Number of acute compartment syndrome conditions during hospitalisation 30 days
Secondary Number of acute compartment syndrome conditions after 1 year Number of acute compartment syndrome conditions after 1 year 1 year
Secondary Incidence of death 1 year Mortality 1 year after admission 1 year
Secondary Incidence of death during hospitalisation Mortality during primary hospitalisation 30 days
Secondary Lenght of stay during primary hospitalisation Lenght of stay during primary hospitalisation 30 days
Secondary Number of pack-years Smoking habit; number of pack-years by participants 30 days
Secondary Intravenous fluid Intravenous fluid given during surgery (ml) 12 hours
Secondary Vasoactive drugs Vasoactive drugs given during surgery (microgram) 12 hours
Secondary Tissue temperature level Tissue temperature level (grade Celcius) during insertion period 10 days
Secondary IscAlert functionality Number of hours with a well-functioning sensor (giving CO2- and temperature data) 10 days
Secondary Intracompartmental pressure Intracompartmental pressure (mmHg) measured in anterior compartment of the injured leg 10 days
Secondary Systolic blood pressure during hospitalisation Systolic blood pressure (mmHg) during hospitalisation 10 days
Secondary Diastolic blood pressure during hospitalisation Diastolic blood pressure (mmHg) during hospitalisation 10 days
Secondary Peripheral pulse during hospitalisation Peripheral distal pulse (rate/minute) at the injured leg during hospitalisation 10 days
Secondary Hemoglobin Hemoglobin (g/dL) level during hospitalisation 10 days
Secondary Creatine kinase Creatine kinase (U/L) level during hospitalisation 10 days
See also
  Status Clinical Trial Phase
Completed NCT01686984 - Influence of Inspiratory Flow Pattern on Exchange of Carbon Dioxide in Humans Without Primary Lung Disease N/A
Completed NCT04879875 - New Method for Real-time Detection of Tissue Ischemia (ISCALERT) N/A
Completed NCT02563132 - Carbon Dioxide Insufflation Colonoscopy in IBD Patients N/A
Completed NCT00520416 - Prospective, Non-Randomized Evaluation of Carbon Dioxide Gas as a Contrast Agent in Comparison With Iodinated Contrast in Endovascular Aneurysm Repair N/A
Recruiting NCT04445909 - Validation of Continuous Transcutaneous Carbon Dioxide Monitoring in VA-ECMO Patients
Completed NCT05114993 - The Effect of Wearing Masks on End-tidal Carbon Dioxide and Pulse Oximetry N/A
Recruiting NCT05297266 - Early Discovery of Ischemia After Replantation Surgery of the Extremities N/A
Withdrawn NCT04893473 - New Method for Real-time Detection of Tissue Ischemia
Recruiting NCT04548687 - a Randomized Clinical Trial Evaluating the Effectiveness of Carbon Dioxide Use in Cardiac Surgery N/A
Completed NCT04588272 - Non Invasive End Tidal Carbon Dioxide Monitoring During Moderate Sedation
Recruiting NCT05051397 - CO2 Modulation in Endovascular Thrombectomy for Acute Ischemic Stroke Phase 2
Recruiting NCT02032355 - The Feasibility of PetCO2 Prediction Hypotension Under Spinal Anesthesia for Cesarean Section N/A
Completed NCT04761237 - The Value of Central Venous-arterial Carbon Dioxide Difference N/A
Completed NCT05497375 - EtCO2 Level to Control Intraoperative Bleeding and Improve the Quality of Surgical Field Vision in Septorhinoplasty N/A